Aspire Biopharma Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
ASBP$8.52+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| For the Years Ended December 31, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| CASH FLOWS FROM OPERATING ACTIVITIES | |||
| Net loss | $(24,480,848) | $(1,309,872) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Amortization of debt discount | 8,019,448 | - | |
| Initial recognition of forward purchase agreement liability | 95,062 | - | |
| Issuance of commitment shares under ELOC agreement | 275,000 | - | |
| Loss on extinguishment of debt | 364,109 | - | |
| Change in fair value of derivative liabilities and convertible notes | (3,860,889) | - | |
| Stock-based compensation | 14,131,250 | - | |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | 174,254 | (109,356) | |
| Inventories | (253,160) | - | |
| Accounts payable | (323,776) | 247,846 | |
| Accrued expenses | 1,047,088 | - | |
| Due to related party | - | 906,196 | |
| Other current liabilities | (111,026) | - | |
| NET CASH FLOWS USED IN OPERATING ACTIVITIES | (4,923,488) | (265,186) | |
| CASH FLOWS FROM FINANCING ACTIVITIES | |||
| Issuance of common stock | - | 257,645 | |
| Proceeds from recapitalization | 265,827 | - | |
| Proceeds from issuance of convertible notes | 10,250,000 | - | |
| Repayment of convertible notes | (3,032,645) | - | |
| Transaction costs paid in connection with convertible notes | (907,499) | - | |
| Proceeds from notes payable - related party | 50,000 | - | |
| Repayment of notes payable – related party | (701,924) | - | |
| NET CASH FLOWS PROVIDED BY FINANCING ACTIVITIES | 5,923,759 | 257,645 | |
| NET CHANGE IN CASH | 1,000,271 | (7,541) | |
| CASH, BEGINNING OF THE YEAR | 3,633 | 11,174 | |
| CASH, END OF THE YEAR | $1,003,904 | $3,633 | |
| Supplemental disclosure of noncash investing and financing activities: | |||
| Accounts payable and other liabilities combined, net | $4,868,403 | $ | - |
| Shares issued pursuant to settlement agreement | $317,250 | $ | - |
| Issuance of shares in reverse recapitalization | $4,602,576 | $ | - |
| Conversion of warrants | $14 | $ | - |
| Conversion of convertible notes | $9,523,683 | $ | - |
| Issuance of shares under working capital loans and non redemption agreements | $14 | $ | - |
| Supplemental cashflow information: | |||
| Cash paid for interest | $44,388 | $ | - |
The accompanying notes are an integral part of these consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.